|

Multiple Sclerosis Clinical Trials in Los Angeles, CA

16 recruiting studies within 50 miles

Phase
Trial Phase Dist.
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPhase 3<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
TSC Biosample Repository and Natural History Database—<1 mi
Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)N/A<1 mi
MS-ResearchBiomarkerS—<1 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyPhase 2<1 mi
Central Vein Sign in Multiple Sclerosis Extension StudyN/A<1 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisPhase 2<1 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPhase 37 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—7 mi
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisPhase 37 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease—14 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 322 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 329 mi
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Phase 136 mi
Entire-body PET Scans for Multiple SclerosisEarly 148 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.